← Compound index
RESEARCH FAMILY / MYELOPEPTIDES

Myelopid & MP-1–MP-6Миелопид / миелопептиды

A family of peptides from bone marrow. Myelopid is the original mixture, and MP-1 through MP-6 are individual peptides.

Immune FunctionRecovery
Source linked

What the studies found

Animal research · 2026

Spinorphin reduced migraine-like responses in rats

Migraine-like responses
Mechanical hypersensitivity and CGRP-related measures reducedRat model
Opioid-receptor involvement
Effects attenuated by nalmefene
Sumatriptan combination
Greater inhibition of capsaicin-evoked CGRP releaseEx vivo endpoint; not human combination efficacy

Spinorphin reduced mechanical hypersensitivity, c-Fos, CGRP and meningeal mast-cell degranulation in a rat migraine model. Nalmefene attenuated these effects. In ex vivo preparations, Spinorphin reduced capsaicin-evoked CGRP release and enhanced sumatriptan’s inhibitory effect on that endpoint.

Study notes · methods, sources and limitations

Participants or model Male Wistar rats with nitroglycerin-induced migraine-like responses; complementary ex vivo hemiskull preparations.

Important limitations

  • Experimental rat and ex vivo findings, not a human migraine trial. A combined effect on CGRP release is not established clinical synergy with sumatriptan. These are Spinorphin results, not results for every myelopeptide.

The European journal of neuroscience 64(8) · Journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 2026

Spinorphin reduced experimental seizures and associated neurochemical changes

Models
Two acute seizure models: pentylenetetrazole and penicillin
Seizure activity
Behavioral seizures and cortical spike frequency reducedNumerical reduction not supplied by the abstract
Memory
Passive-avoidance retention improved

Spinorphin reduced behavioral seizures and cortical epileptiform spike frequency, improved passive-avoidance retention, and altered glutamate, GABA and inflammatory/oxidative markers. Nalmefene substantially attenuated the effects but did not fully reverse them, suggesting both opioid-related and other mechanisms.

More reported outcomes
Nalmefene challenge
Substantial but incomplete attenuation of effects
Study notes · methods, sources and limitations

Participants or model Rat pentylenetetrazole- and penicillin-induced acute seizure models.

Important limitations

  • Acute rat seizure models, not clinical epilepsy evidence. The abstract does not provide numerical effect sizes or group-specific seizure counts. Spinorphin results cannot be assigned to all members of the myelopeptide family.

Neurochemical research 51(6) · Journal publication

Original source or citation ↗

Study results and tables ↗

Lab research · 2000

A new endogenous differentiating factor (myelopeptide-4) for myeloid cells.

MP-4 (FRPRIMTP), isolated from porcine marrow culture, altered differentiation markers and morphology in HL-60 and K-562 leukemia cell lines. This was not a leukemia treatment trial.

Study notes · methods, sources and limitations

Participants or model Human leukemia cell lines; porcine marrow-derived peptide

Important limitations

  • Preclinical findings do not establish human benefit or safety. Abstract only. Full methods and independent replication remain unconfirmed.

FEBS letters · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Myelopid & MP-1–MP-6

Names in this research collection

Myelopid · MP-1 · MP-2 · MP-3 · MP-4 · MP-5 · MP-6 · Bivalen · Seramil · LVV-H3 · LVV-hemorphin-3 · Spinorphin · Tynorphin

Research background

A marrow-peptide family separating the original mixture from defined isolates and later synthetic research. Each member needs its own evidence.

Compound class
Peptide research family
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

No human treatment trial assessed for this family

Study methods

Member-specific studies; patents and archival leads identified separately

Independent replication

Independent replication not established by the records collected here

Source access

Primary abstracts, selected full texts, patents and explicit retrieval targets

Safety evidence

Cell and animal effects do not establish human safety; analogues may differ

Open a topic for the evidence assessment.

More findings, background and history
IDENTITY / MEMBER-SPECIFIC EVIDENCE

Inside this research family

Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.

Research objects, findings and source boundaries
MemberIdentityWhat the source supports
MP-1FLGFPT; historical identification lead

Original isolation and functional source recovery pending.

Original-source recovery pending
MP-2LVVYPW

T-cell IL-2 studies and mouse tumor experiments; Bivalen formulation equivalence needs separate verification.

Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus. ↗

Effect of myelopeptide-2 on the development of spontaneous and urethane-induced tumors in mice. ↗

MP-3LVCYPQ

Patent isolate; a Seramil name/sequence link remains to be independently resolved.

Myelopeptides and their therapeutic use — US6469137B1 ↗

MP-4FRPRIMTP

Original FEBS publication supports this octapeptide and cell differentiation findings.

A new endogenous differentiating factor (myelopeptide-4) for myeloid cells. ↗

Induction of differentiation in leukemic cell strains with myelopeptide-4. ↗

MP-5 / MP-6VVYPD / VDPP

Patent-defined isolates with distinct experimental profiles, not interchangeable immune stimulants.

Myelopeptides and their therapeutic use — US6469137B1 ↗

Myelopid mixtureMultiple marrow-derived components

Opioid-related and antibody-stimulating fractions separated chromatographically.

Participation by opioids in the immunostimulatory activity of myelopeptides. ↗

Interpretation and open questions

The hemoglobin/hemorphin connection is a sequence-lineage research lead. It does not make every MP peptide an opioid agonist.

Spinorphin and tynorphin are adjacent hemoglobin-fragment programs, not synonyms for MP-2. A later recombinant precursor and conflicting MP-4 transcriptions require separate source review.

The citation identifies Petrov, Mikhailova, Fonina and Stepanenko’s Myelopeptides (Nauka, 2001, ISBN 5-02-006503-X). The full text is unavailable here.

Explore the Russian peptide research map ↗

What remains unclear

The available experimental studies leave human benefit and safety uncertain.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2002 · US6469137B1 · Myelopeptides and their therapeutic use — US6469137B1Molecule · Approximately 60% mature monocyte/macrophage forms reported among the examined cells

Reported findings

MP-4 induced a differentiation-like phenotype in leukemia cells; the individual myelopeptides did not act uniformly across the assays.

MP-4 leukemia-cell differentiation
Approximately 60% mature monocyte/macrophage forms reported among the examined cellsIn-vitro morphology endpoint, not a leukemia remission rate
Short-term viability
No visible damage reported for the tested MP-3–MP-6 cell-culture conditions24-hour observationA limited cell assay, not clinical or long-term safety
All reported results, comparisons and limitations →

Molecule. Defined myelopeptide-related sequences and their proposed immune applications; the patent does not validate every Myelopid preparation.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
US6469137B1 ↗ · 2002-10-22
Earliest priority / filing
1997-01-07 / 1998-01-07
Original applicant / assignee
Primamedic Ltd
Indexed status
Expired - Fee Related · checked 2026-11-06
Patent family
10805577 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Myelopeptides and their therapeutic use

Inventors: Rem V. Petrov; Augusta A. Mikhailova; Larissa A. Fonina; Sergei A. Guriyanov.

US6469137B1 · US20030083236A1 · EP0960122A1 · JP2001508435A · AU728539B2 · CA2274731A1 · GB9700154D0 · NZ336243A · RU2198178C2 · WO1998030581A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2026

Spinorphin Ameliorates Nitroglycerin-Induced Migraine-Like Responses and Trigeminovascular Neuroinflammation Potentially Through Opioid Receptor-Mediated Mechanisms

Spinorphin reduced mechanical hypersensitivity, c-Fos, CGRP and meningeal mast-cell degranulation in a rat migraine model. Nalmefene attenuated these effects. In ex vivo preparations, Spinorphin reduced capsaicin-evoked CGRP release and enhanced sumatriptan’s inhibitory effect on that endpoint.

Study notes and original source
2026Animal / experimentalEnglish abstract

Spinorphin Ameliorates Nitroglycerin-Induced Migraine-Like Responses and Trigeminovascular Neuroinflammation Potentially Through Opioid Receptor-Mediated Mechanisms

· Journal publication

Demir C, Torun IE, Baranoglu Kilinc Y, Kilinc E · The European journal of neuroscience 64(8)

Spinorphin reduced mechanical hypersensitivity, c-Fos, CGRP and meningeal mast-cell degranulation in a rat migraine model. Nalmefene attenuated these effects. In ex vivo preparations, Spinorphin reduced capsaicin-evoked CGRP release and enhanced sumatriptan’s inhibitory effect on that endpoint.

Results and tables

Reported findings and study design

Spinorphin reduced mechanical hypersensitivity, c-Fos, CGRP and meningeal mast-cell degranulation in a rat migraine model. Nalmefene attenuated these effects. In ex vivo preparations, Spinorphin reduced capsaicin-evoked CGRP release and enhanced sumatriptan’s inhibitory effect on that endpoint.

Population or model Male Wistar rats with nitroglycerin-induced migraine-like responses; complementary ex vivo hemiskull preparations.

Results · Indexed abstract checked
MeasureResultComparison, timing and statistics
Migraine-like responsesMechanical hypersensitivity and CGRP-related measures reducedRat model
Opioid-receptor involvementEffects attenuated by nalmefene
Sumatriptan combinationGreater inhibition of capsaicin-evoked CGRP releaseEx vivo endpoint; not human combination efficacy

Experimental rat and ex vivo findings, not a human migraine trial. A combined effect on CGRP release is not established clinical synergy with sumatriptan. These are Spinorphin results, not results for every myelopeptide.

Source for these results ↗ · Reviewed 2026-10-31

Population / setting
Male Wistar rats with nitroglycerin-induced migraine-like responses; complementary ex vivo hemiskull preparations.
Source reviewed
Primary publication metadata and indexed abstract checked through Europe PMC on 31 October 2026. No unavailable effect sizes inferred.
Study limitations
  • Experimental rat and ex vivo findings, not a human migraine trial. A combined effect on CGRP release is not established clinical synergy with sumatriptan. These are Spinorphin results, not results for every myelopeptide.

Reviewed 2026-10-31.

Read the source ↗

Animal research · 2026

Spinorphin Attenuates Acute Experimental Seizures and Associated Neurochemical Alterations: Possible Involvement of Opioid Receptors

Spinorphin reduced behavioral seizures and cortical epileptiform spike frequency, improved passive-avoidance retention, and altered glutamate, GABA and inflammatory/oxidative markers. Nalmefene substantially attenuated the effects but did not fully reverse them, suggesting both opioid-related and other mechanisms.

Study notes and original source
2026Animal / experimentalEnglish abstract

Spinorphin Attenuates Acute Experimental Seizures and Associated Neurochemical Alterations: Possible Involvement of Opioid Receptors

· Journal publication

Torun IE, Baranoglu Kilinc Y, Kilinc E, Ankarali S · Neurochemical research 51(6)

Spinorphin reduced behavioral seizures and cortical epileptiform spike frequency, improved passive-avoidance retention, and altered glutamate, GABA and inflammatory/oxidative markers. Nalmefene substantially attenuated the effects but did not fully reverse them, suggesting both opioid-related and other mechanisms.

Results and tables

Reported findings and study design

Spinorphin reduced behavioral seizures and cortical epileptiform spike frequency, improved passive-avoidance retention, and altered glutamate, GABA and inflammatory/oxidative markers. Nalmefene substantially attenuated the effects but did not fully reverse them, suggesting both opioid-related and other mechanisms.

Population or model Rat pentylenetetrazole- and penicillin-induced acute seizure models.

Results · Indexed abstract checked
MeasureResultComparison, timing and statistics
ModelsTwo acute seizure models: pentylenetetrazole and penicillin
Seizure activityBehavioral seizures and cortical spike frequency reducedNumerical reduction not supplied by the abstract
MemoryPassive-avoidance retention improved
Nalmefene challengeSubstantial but incomplete attenuation of effects

Acute rat seizure models, not clinical epilepsy evidence. The abstract does not provide numerical effect sizes or group-specific seizure counts. Spinorphin results cannot be assigned to all members of the myelopeptide family.

Source for these results ↗ · Reviewed 2026-10-31

Population / setting
Rat pentylenetetrazole- and penicillin-induced acute seizure models.
Source reviewed
Primary publication metadata and indexed abstract checked through Europe PMC on 31 October 2026. No unavailable effect sizes inferred.
Study limitations
  • Acute rat seizure models, not clinical epilepsy evidence. The abstract does not provide numerical effect sizes or group-specific seizure counts. Spinorphin results cannot be assigned to all members of the myelopeptide family.

Reviewed 2026-10-31.

Read the source ↗

Lab research · 2000

A new endogenous differentiating factor (myelopeptide-4) for myeloid cells.

MP-4 (FRPRIMTP), isolated from porcine marrow culture, altered differentiation markers and morphology in HL-60 and K-562 leukemia cell lines. This was not a leukemia treatment trial.

Study notes and original source
2000In vitroEnglish abstract

A new endogenous differentiating factor (myelopeptide-4) for myeloid cells.

Strelkov LA, Mikhailova AA, Fonina LA, Petrov RV · FEBS letters

MP-4 (FRPRIMTP), isolated from porcine marrow culture, altered differentiation markers and morphology in HL-60 and K-562 leukemia cell lines. This was not a leukemia treatment trial.

Population / setting
Human leukemia cell lines; porcine marrow-derived peptide
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Lab research · 2005

Induction of differentiation in leukemic cell strains with myelopeptide-4.

MP-4 increased differentiation-associated antigens and mature-cell features in leukemia cell cultures, with phagocytosis also examined. The report extends laboratory characterization rather than demonstrating clinical efficacy.

Study notes and original source
2005In vitroEnglish abstract

Induction of differentiation in leukemic cell strains with myelopeptide-4.

Kirilina EA, Suvorov NI, Popova SS, Khaidukov SV, Rapoport EM, Fonina LA, Mikhailova AA · Bulletin of experimental biology and medicine

MP-4 increased differentiation-associated antigens and mature-cell features in leukemia cell cultures, with phagocytosis also examined. The report extends laboratory characterization rather than demonstrating clinical efficacy.

Population / setting
HL-60, K-562 and THP-1 cell lines
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Lab research · 2006

Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus.

MP-2 (LVVYPW) restored IL-2 production and receptor expression in experimentally suppressed human T cells. Human-derived cells do not make this a human treatment trial.

Study notes and original source
2006In vitroEnglish abstract

Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus.

Mikhailova AA, Belevskaya RG, Kalyuzhnaya M, Fonina LA, Liashenko VA, Petrov RV · Journal of immunotherapy (Hagerstown, Md. : 1997)

MP-2 (LVVYPW) restored IL-2 production and receptor expression in experimentally suppressed human T cells. Human-derived cells do not make this a human treatment trial.

Population / setting
Human T-cell cultures exposed to tumor-conditioned medium or measles virus
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2002

Effect of myelopeptide-2 on the development of spontaneous and urethane-induced tumors in mice.

MP-2 altered the appearance and number of spontaneous and urethane-induced lung tumors in mice. Laboratory tumor outcomes do not establish cancer prevention or treatment in people.

Study notes and original source
2002Animal / experimentalEnglish abstract

Effect of myelopeptide-2 on the development of spontaneous and urethane-induced tumors in mice.

Mikhailova AA, Kirilina EA, Morozova OV, Turusov VS · Bulletin of experimental biology and medicine

MP-2 altered the appearance and number of spontaneous and urethane-induced lung tumors in mice. Laboratory tumor outcomes do not establish cancer prevention or treatment in people.

Population / setting
Mice; spontaneous and carcinogen-induced tumors
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 1990

Participation by opioids in the immunostimulatory activity of myelopeptides.

Antibody-stimulating material and beta-endorphin eluted in different chromatographic fractions. The original mixture’s opioid-related effects cannot be assigned to every defined MP-1–MP-6 peptide.

Study notes and original source
1990Animal / experimentalEnglish abstract

Participation by opioids in the immunostimulatory activity of myelopeptides.

Zakharova LA, Belevskaya RG, Yanovskii OG · Biomedical science

Antibody-stimulating material and beta-endorphin eluted in different chromatographic fractions. The original mixture’s opioid-related effects cannot be assigned to every defined MP-1–MP-6 peptide.

Population / setting
Mice, marrow peptide fractions and chromatography
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Experiment described in a patent · 2002

Myelopeptides and their therapeutic use — US6469137B1

MP-3, MP-4, MP-5 and MP-6 were described as marrow-culture isolates with nonuniform immune, differentiation and antiviral assay results. The patent does not establish that the mixture or every member shares these activities.

MP-4 leukemia-cell differentiation · Approximately 60% mature monocyte/macrophage forms reported among the examined cells · In-vitro morphology endpoint, not a leukemia remission rate

Study notes and original source
2002Patent / reported experimentsFull text available

Myelopeptides and their therapeutic use — US6469137B1

· Primary source linked above

MP-3, MP-4, MP-5 and MP-6 were described as marrow-culture isolates with nonuniform immune, differentiation and antiviral assay results. The patent does not establish that the mixture or every member shares these activities.

Results and tables

Reported patent results

Reported findings

MP-4 induced a differentiation-like phenotype in leukemia cells; the individual myelopeptides did not act uniformly across the assays.

Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.

Population or model Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.

Results · MP-4 differentiation section and limited cell-viability observations; no pathogen-production methods included.
MeasureResultComparison, timing and statistics
MP-4 leukemia-cell differentiationApproximately 60% mature monocyte/macrophage forms reported among the examined cellsIn-vitro morphology endpoint, not a leukemia remission rate
Short-term viabilityNo visible damage reported for the tested MP-3–MP-6 cell-culture conditionsA limited cell assay, not clinical or long-term safety · 24-hour observation

Cell differentiation, assay response and lack of visible short-term damage do not establish efficacy or safety of Myelopid in patients. Individual peptides and mixtures must remain distinct.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.
Source reviewed
Selected original-source text checked; full methodological review pending.
Study limitations
  • Patent efficacy proposals are not clinical evidence.
  • Commercial product names require formulation-specific confirmation.

Reviewed 2026-11-06.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗